Introduction
Frailty is increasingly being recognized as an important effect modifier of traditional cardiac outcome measures. 1, 2 Frailty is a clinical syndrome in which there is physiologic dysregulation. Clinically, this translates into limited functional reserves and increased vulnerability to any stressor that threatens homeostasis. Frail patients are at greater risk for death, increased length of hospitalization, falls, institutional placement, and functional decline.
1,2
Frailty has been noted in as many as 75% of patients with heart failure, although these studies have not distinguished between heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
1,3
Since HFpEF is predominantly a disorder of older persons with multiple medical co-morbidities, frailty is particularly important to characterize in this population. Furthermore, the relationship between frailty and outcomes in HFpEF has not yet been evaluated.
Frailty has been measured using a number of different instruments in clinical trials and observational studies. 4, 5 The approach used to conceptualize frailty generally falls into two groups: frailty defined by phenotype (sometimes termed physical frailty) and frailty defined by a deficit accumulation approach (sometimes termed multi-dimensional frailty). 2, 6 -8 This latter approach is a particularly suitable method to rely upon when evaluating frailty and its relationship to outcomes retrospectively from information available in large datasets. As such, we utilized the deficit accumulation approach to examine the prevalence and impact of frailty in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) HFpEF trial. The study design and principal results of the TOPCAT trial have previously been reported. 9 Briefly, this trial compared the use of spironolactone 15-45 mg daily with placebo in patients with symptomatic HFpEF. Overall, 3445 patients were randomized in six countries. The primary study outcome was a composite of death from cardiovascular causes, aborted cardiac arrest or hospitalization for the management of heart failure. Secondary outcomes included cardiovascular death, heart failure hospitalization and all-cause mortality. Although the overall study result was neutral with regard to the primary endpoint, spironolactone was associated with a reduction in both cardiovascular death and heart failure hospitalization in a post-hoc analysis of subjects enrolled in the Americas.
For this particular study, our aims were to (i) construct a frailty index (FI) based on a deficit accumulation approach, (ii) report the prevalence of frailty in TOPCAT participants, (iii) identify the impact of frailty status on primary and secondary outcomes, and (iv) determine if frailty status modified the impact of spironolactone treatment on these outcomes.
Methods

Study cohort
This was a post-hoc analysis of data obtained in the TOPCAT trial. Because of previously described regional differences in patient characteristics, outcomes, adherence to study drug, and response to spironolactone between subjects enrolled in Russia/Georgia and the Americas, this analysis was limited to those participants enrolled in the Americas (United States, Canada, Brazil, and Argentina) (n = 1767), analogous to the approach utilized in previous analyses. 10 -12 
Background of the frailty index
A standard procedure to construct a FI using the deficit accumulation approach was utilized. 8, 13 This approach has its origins in explaining how complex systems degrade over time and ultimately fail. Derived from the Canadian Study of Health and Aging, 8 the deficit accumulation approach conceptualizes frailty on a continuum of increasing vulnerability. A frail person is not necessarily 'sicker' and may not have any overt manifestations of an illness. However, due to a reduction in functional reserve capacity -captured as a higher FI -the frail person's ability to compensate following perturbation in the homeostatic balance becomes impaired and physiologic decompensation ensures. A 'stressor' such as fever or dehydration is often all that is required to upset the frail person's homeostatic balance. 14 In contrast to traditional risk models, when using the FI accumulation of deficits model, it is the proportion of deficits present rather than their severity that is important in characterizing frailty. include signs, symptoms, diseases, disabilities, and laboratory abnormalities and, while the precise deficits being measured are not constant across all studies, the methodology emphasizes these deficits should generally be more prevalent but not necessarily occur linearly with older age (e.g. frailty is not just a product of age). At least 30 deficits should be included. The deficits together should encompass several organ systems and be associated with adverse health outcomes. 7, 13 A FI is calculated by taking the total sum of deficits present divided by the number of deficits measured. Although the FI conceptualizes frailty on a continuum, a FI of > 0.21 is the generally accepted cut-off to define clinical frailty in community dwelling individuals. 14, 15 An advantage of the deficit accumulation approach to define frailty is the ratio of the deficits to total number of systems can be compared across studies that utilize different measures. For example, prior studies have identified an upper limit of FI of 0.67; higher values are not considered compatible with life.
Construction of a frailty index
For this particular analysis, a FI was constructed for each participant utilizing the methodology described previously. Variables considered for index inclusion covered demographic data, vital signs, laboratory data, co-morbid illnesses, total number of medications, and self-reported quality of life measures. Quality of life measures included questions on functional status, e.g. ability to complete activities of daily living. After excluding variables missing in more than 6% of participants, 39 variables were utilized to calculate a FI for each participant. A complete description of variables included in the FI along with the scoring system is available in the online supplementary Table S1 . Each variable was assigned a value on a scale between 0 (not present) and 1 (present at the greatest severity). If a participant was missing a variable, this was scored as being not present, and the FI denominator adjusted accordingly. This scoring scheme was similar to that used in other analyses.
16 -18 Congruent with the described standard procedure, a FI was calculated by taking the sum of the total number of variables present for each subject divided by the total number of variables measured, giving a FI range of 0-1. Participants with the lowest score are the least frail while those with the highest score are the most frail. Based on the FI distribution in this analysis, participants were divided into quartiles: Class 1, FI < 0. 
Statistical analysis
Continuous variables are reported using means and standard deviations, or medians and interquartile ranges (IQR) for skewed variables. Dichotomous variables are reported using counts and percentages. Tests for trend across frailty score categories are conducted using linear regression, Cuzick's nonparametric trend test, and Cochran-Armitage test for trend, respectively. Clinical outcomes were analysed using Cox proportional hazards models. All analyses were conducted using data from the Americas (United States, Canada, Brazil, and Argentina). P-values < 0.05 are considered significant. All analyses were conducted using STATA 13 (Stata Corp., College Station, TX, USA).
We determined the association between baseline frailty status and the pre-specified primary and secondary endpoints in TOPCAT participants. We also assessed the potential interaction between frailty and treatment effect by examining variation in the clinical benefits of spironolactone among categories defined by baseline frailty class. 
Results
The FI was normally distributed (Figure 1 ). For the cohort as a whole (mean age 71.5 years, 49% female), the mean FI at baseline was 0.37 ± 0.11 (median 0.36; IQR 0.29-0.44). Ninety-four percent had a FI > 0.21, the typical threshold to define frailty in ambulatory populations. Table 1 shows the baseline characteristics of subjects stratified by frailty class. There was no difference in baseline ejection fraction among the different frailty classes. Baseline New York Heart Association class was generally higher in those with greater frailty. Higher FI values were also associated with greater prevalence of co-morbid illnesses, greater abnormal laboratory levels of serum creatinine, albumin, haemoglobin and a lower estimated glomerular filtration rate. Diabetes was more prevalent in those with greater frailty (20.4% in Class 1 vs. 77.5% in Class 4; P < 0.001). Values are mean ± standard deviation, number (%), or median (interquartile range). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; eGFR, estimated glomerular filtration rate; BP, blood pressure; HF, heart failure; MI, myocardial infarction; NYHA, New York Heart Association. 
Values are given as unadjusted hazard ratio per 0.1 point increase in FI (95% confidence interval), P-value, and number of events. CV, cardiovascular; FI, frailty index; HF, heart failure.
There was an inverse relationship between mean age and frailty. Class 4 subjects (69 ± 9 years) were significantly younger compared to Class 1 subjects (73 ± 10 years; P < 0.001). In addition, greater frailty was significantly associated with both higher systolic blood pressure and pulse pressure. A greater percentage of subjects were using heart failure medications (diuretics, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and beta-blockers) at baseline as frailty severity increased. Body mass index was highest in the most frail class. Table 2 shows the relationship between the FI and outcome events in all subjects and according to frailty class. FI is presented as a linear variable and hazard ratios (HR) are represented per 0.10 point increase in FI. Increasing frailty was significantly associated with an increase in the primary composite outcome (death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure) as well as for all of the following individual outcomes: cardiovascular mortality, all-cause mortality, and heart failure hospitalization. Frailty conferred the greatest risk for heart failure hospitalization with a HR of 1.50 (1.37-1.63; P < 0.001). For a different view, Figure 2 presents the outcomes for all-cause mortality as Kaplan-Meier curves. We also examined the competing outcomes of cardiovascular death, heart failure hospitalizations, non-cardiovascular death, and non-cardiovascular hospitalizations (online supplementary Table S2 ). We found that as frailty severity increased, there was an associated increase in non-cardiovascular death, all-cause hospitalization, cardiovascular hospitalization, and non-cardiovascular hospitalization. Figure 3 examines the interaction between treatment assignment and frailty class with regard to the pre-specified outcomes. 
Impact of frailty on outcomes
Discussion
The most compelling finding of this analysis is that TOPCAT participants had a high median FI, with over 90% meeting the commonly accepted deficit threshold for multi-dimensional frailty in community dwelling adults (mean FI 0.37 ± 0.11; median 0.36; IQR 0.29-0.44). The degree of frailty noted in these ambulatory TOP-CAT participants is comparable to that reported in hospitalized patients and likely reflects the additional impact of the HF syndrome on physiologic reserve, and, ultimately, on frailty. 18 The FI can also be interpreted relative to chronologic age. Rockwood and Mitnitski 19 found the mean FI of a 71-year-old was 0.12. In this same study, all participants with a mean FI > 0.3 were at least 95 years of age. Using this concept, a 71-year-old person with a FI of 0.38 (mean age and FI of participants in this current analysis) can be biologically considered to be 95 years old with respect to frailty.
Two large hypertension trials of older community dwelling adults have reported outcomes stratified by frailty using a similar deficit accumulation approach. In the Hypertension in the Very Elderly Trial (HYVET), mean and median FI for participants were 0.19 and 0.17 (IQR 0.11-0.24), respectively.
17 Similarly, the median FI in participants of the Systolic Blood Pressure Intervention Trial (SPRINT) was 0.16 (IQR 0.11-0.22). 16 The average participant age in these trials was older (mean age 83.5 years in HYVET and 79.9 years in SPRINT) than in TOPCAT (mean age 71.5 years). The finding that despite younger age, participants in the TOPCAT trial had higher degrees of frailty and that within the trial, age was inversely associated with frailty supports the complex nature of the HFpEF cardio-geriatric syndrome 1, 5, 20 and suggests that frailty in patients with HFpEF is dominated by factors other than age. The significantly higher event rates noted in the TOPCAT trial when compared to other trials also support the higher degree of frailty seen in TOPCAT. The TOPCAT trial reported annual event rates of 5.9% and 6.6% of the primary outcome in the treatment and placebo group, respectively. Other HFpEF trials have also reported higher event rates. Annual event rates for the primary outcome in I-PRESERVE were 10.0% and 10.5% for the active and placebo arm, respectively. 21 In contrast, the annual event rates noted for the primary outcomes in HYVET, SPRINT, and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trials for the treatment and placebo groups were much lower (1.24% and 1.7%, 1.65% and 2.19%, and 1.87% and 2.09%, respectively). 22 -24 While the outcomes measured were not exactly the same across these trials, the nearly three-fold greater event rates in TOPCAT are consistent with the average degree of frailty being greater in TOPCAT relative to these hypertension trials while also reflecting the mortality associated with heart failure.
This analysis had some unexpected findings. Increasing age, systolic blood pressure, pulse pressure and medication use were all inversely associated with frailty severity. While HFpEF is a cardio-geriatric syndrome, if HFpEF develops at a younger age, it is likely due to a higher burden of co-morbidities and functional impairment. This manifests as a higher FI. A finding in this analysis supportive of this notion is that diabetes was present in 20% of those in the lowest frailty class (Class 1), relative to a prevalence of 77.5% in the most frail class (Class 4). Another unexpected finding was that body mass index was greatest in the most frail class. While this finding contradicts the general view that in the geriatric population low body mass index/weight loss is often asso- recently in other analyses. A recent analysis of TOPCAT participants demonstrated that abdominal obesity was associated with increased risk of all-cause mortality. 23 Additionally, the existence of a unique HFpEF phenotype in obese patients has been postulated. 24 We believe this finding deserves further investigation.
Another important finding in this analysis was that greater frailty in TOPCAT participants was associated with an increase in the primary and secondary study outcomes. The strongest association was observed for the secondary outcome of heart failure hospitalization. Although limited data are available to confirm this finding in HFpEF, studies in other populations and disease conditions have highlighted similar results. For example, McNallan et al. 3 found an association between increasing frailty and increased risk for hospitalization due to any cause. Additionally, a recent analysis of TOPCAT participants found self-reported poor to intermediate baseline physical activity was associated with increased heart failure hospitalization and mortality.
10 This is important to highlight as physical activity measured in various forms has been proposed as a possible surrogate for defining frailty. 25 Finally, this analysis noted no interaction between frailty class and the treatment effect of spironolactone on outcomes. In light of the common reluctance of clinicians to introduce medications to patients that are perceived to be frail, this finding deserves emphasis. The lack of uniform effect with respect to cardiovascular disease and total mortality by FI (e.g. frailty Class 3 for all-cause mortality) is not well understood. Since this is a post-hoc analysis and frailty groups were not prospectively defined in the initial study, we cannot discount the possibility of chance playing a role in this finding. Whether the heart failure aspect of the frailty syndrome or frailty itself is responsive to spironolactone remains to be determined and speculative. Based on this analysis, however, P = 0.55 
Strengths and clinical implications
A strength of this analysis is that it is the first, to our knowledge, to describe frailty in a large, well characterized population of HFpEF patients from a randomized clinical trial. Because we used a well described standard process for constructing the FI in this analysis, our findings can be compared with other studies which also utilize the same approach to frailty, even if the deficits measured as part of the FI in those studies were different. Furthermore, we believe there is added value in evaluating outcomes from the point of view of frailty and not only from the view of a traditional risk prediction model.
Another strength of this analysis is its clinical implications. There has been a recent call to increase the number of studies incorporating the frailty syndrome.
5,20,25 -27 While uniformly defining frailty across studies remains a challenge, the FI derived from the deficit accumulation approach has been widely utilized and validated across several patient populations 1, 14, 15, 18, 28 and in clinical trials. 16, 17 This approach is particularly well suited to characterize frailty at a population level where the clinical phenotypic characteristics are often not available such is the case in this post-hoc analysis of prospectively collected data. It is not designed to be a . 
Limitations
There are several limitations to acknowledge. First, this is a post-hoc analysis and the frailty classes were not pre-specified nor directly measured. In addition, we did not weight the variables used in the FI. It may be possible to further refine the FI by using continuous variables or weighting factors based on the level of impairment. This is a future direction for research using the FI approach. To be able to compare our findings to other analyses which have utilized the deficit accumulation approach to define frailty, it was important for the authors to follow the standard procedure for creating a FI as defined by Searle et al. 13 We utilized a FI > 0.21 to define frailty in this analysis. This cut-off was derived from community-based cohorts and not heart failure clinical trial datasets. Yet, it has been used in other FI analyses of clinical trial datasets, e.g. HYVET and SPRINT.
16,17 However, we acknowledge that this specific cut-off has not been independently validated in heart failure clinical trial datasets, due to the lack of other frailty assessments available in such datasets for comparison.
Another potential limitation is that some of the items used in the FI score are already known to be associated with outcomes in HFpEF. The Kansas City Cardiomyopathy items measure quality of life symptoms specific to heart failure and one could argue that using EuroQol-5 Dimensions (EQ-5D) quality of life data would better represent quality of life overall. 32 EQ-5D was indeed collected in the TOPCAT trial, however, the response rate was not high enough to meet the minimum requirements to be included in the FI (e.g. data were missing). In addition, the finding of a higher prevalence of co-morbid conditions in the most frail group is not surprising given that some of these co-morbid conditions were part of the FI construct. That said, while the terms disability, co-morbidity, and frailty are frequently used interchangeably, these entities are in fact unique and result in different prognoses. 33, 34 Limiting this analysis to the Americas may be noted as a possible weakness; however, such an approach appears to be reasonable in light of imbalances in outcomes as noted in prior publications. The treatment interaction data must be interpreted with caution as the overall trial was neutral with respect to this endpoint. Lastly, we did not make serial measurements of frailty in TOPCAT, so whether frailty itself can be modified and is responsive to heart failure therapy remains to be determined.
Conclusions
This analysis is the first to describe frailty status in a large population of well characterized HFpEF patients. The most significant finding is that TOCPAT participants were a generally frail group. As the severity of frailty increased, there were associated higher rates in the outcomes of cardiovascular death, heart failure hospitalization, and all-cause mortality. The benefit of spironolactone was not attenuated across the classes of frailty. Future studies in HFpEF patients should incorporate frailty measures in order to further understand this complex cardio-geriatric syndrome and to identify treatments that are effective in frail patients.
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